This brief developed jointly between the NH Comprehensive Cancer Collaboration and the Norris Cotton Cancer Center at Dartmouth Hitchcock discusses the emerging data showing that aspirin use is associated with reduction in colorectal cancer risk. Second, in several randomized placebo-controlled trials, aspirin treatment decreased risk of colorectal adenomas, which are precursors to the majority of colorectal cancers (Cole et al., 2009). Third, there is compelling evidence from a series of recent analyses combining long-term follow-up data on cancer outcomes from randomized controlled trials designed to study cardiovascular disease prevention. In these secondary analyses, low-dose aspirin treatment reduced colorectal cancer incidence and mortality and also overall cancer metastasis and mortality..
Cancer - Colorectal
Chronic disease - Cardiovascular disease